Indian Journal of Clinical Biochemistry

, Volume 26, Issue 2, pp 182–186

Serum total PSA and free PSA in breast tumors

  • Prakruti Dash
  • Sanghamitra Pati
  • Manaswini Mangaraj
  • Pratima Kumari Sahu
  • Prakash Chandra Mohapatra
Original Article

Abstract

Now a days measurement of molecular forms of PSA has gained importance in clinical practice. Several studies have demonstrated the production of PSA in female tissues, such as breast. The present piece of work has been undertaken with an objective to estimate the relative proportion of the molecular forms of PSA in serum along with serum testosterone in benign and malignant breast tumor cases and to analyze their association with the severity of the disease process 34 malignant and 26 benign breast disease cases along with 33 healthy controls of same age group were enrolled in this study for evaluation. Serum testosterone was measured by ELISA, whereas serum total PSA (TPSA) and free PSA (FPSA) were estimated by electrochemiluminescence immunoassay. A significant rise of fasting plasma glucose along with prominent dyslipidemia was observed in breast tumor cases. Marked rise in serum testosterone as well as TPSA and FPSA was documented in both benign and malignant breast tumor cases. Serum testosterone revealed a significant positive association with both TPSA and FPSA pointing towards an etiological association between them. However, surgical removal of tumor mass resulted in a marked decline of presurgical value of both TPSA and FPSA with a non-significant fall in serum testosterone revealing tumor tissue as the source of FPSA and TPSA. Thus, estimation of PSA provides prognostic information that may assist in future treatment.

Keywords

Breast tumors Testosterone TPSA FPSA 

References

  1. 1.
    ICMR Bulletin. Estrogen and breast cancer, Feb 2003,32(2):13–16.Google Scholar
  2. 2.
    McCormack RT, Rittenhouse HG, Finlay JA. Molecular forms of prostate specific antigen and the human kallikrein gene family: a new era. Urology. 1995;45:729–44.PubMedCrossRefGoogle Scholar
  3. 3.
    Catalona WJ, Smith DS, Ratliff TL. Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156–61.PubMedCrossRefGoogle Scholar
  4. 4.
    Filella X, Molina R, Alcover J, Carretero P, Ballesta AM. Detection of nonprostatic PSA in serum and non serum samples from women. Int J Cancer. 1996;68(4):424–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Zarghami N, Grass L, Diamandis EP. Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cancer. 1997;75:579–88.PubMedCrossRefGoogle Scholar
  6. 6.
    Melegos DN, Yu H, Ashok M, Wang C, Stanczyk F, Diamandis EP. Prostate-specific antigen in female serum, a potential new marker for androgen excess. J Clin Endo Metab 1997(b); 82:777–780.Google Scholar
  7. 7.
    Melegos DN, Diamandis EP. Diagnostic value of molecular forms of prostate-specific antigen for female breast cancer. Clin Biochem. 1996;29:193–200.PubMedCrossRefGoogle Scholar
  8. 8.
    Black MH, Giai M, Ponzone R, Sismondi P, Yu H, Diamandis EP. Serum total and free prostate-specific antigen for breast cancer diagnosis in women. Clin Cancer Res. 2000;6:467–73.PubMedGoogle Scholar
  9. 9.
    Romppanen J, Keskikuru R, Kataja V, Eskelinen M, Kosma VM, Savolainen K, et al. Measurement of prostate-specific antigen in detection of benign or malignant disease in women. Br J Cancer. 1999;79:1583–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Narita D, Cimpean AM, Anghel A, Raica M. Prostate-specific antigen value as a marker in breast cancer. Neoplasma. 2006;53(2):161–7.PubMedGoogle Scholar
  11. 11.
    Hautmann S, Huland E, Grupp C, Haese A, Huland H. Super-sensitive prostate specific antigen (PSA) in serum of women with benign breast disease or breast cancer. Anticancer Res. 2000;20(3B):2151–4.PubMedGoogle Scholar
  12. 12.
    Baum M. The Breast. In: Russell RCG, William NS, Bulstrode CJK, editors. Bailey & Love’s short practice of surgery. 24th ed. London: International students Edition; 2004. p. 835–839.Google Scholar
  13. 13.
    American Joint Committee on Cancer (AJCC). In: Greene FL, Page DL, Fleming ID, editors. Cancer staging manual. 6th ed. Springer, New York; 2002. p. 223–240.Google Scholar
  14. 14.
    Kricka LJ. Optical techniques. In: Tietz Textbook of clnical chemistry and molecular diagnostics, 4th ed. 2006; Chapter 3, 84–85.Google Scholar
  15. 15.
    Blackburn GF, Shah HP, Kenten JH. Electrochemiluminescence development of immunoassays and DNA probe assays for clinical diagnostics. Clin Chem. 1991;37:1534–9.PubMedGoogle Scholar
  16. 16.
    Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991;145:907–23.PubMedGoogle Scholar
  17. 17.
    Akdas A, Cevik I, Tarcan T, Turkeri L, Dalaman G, Emerk K. The role of free prostate-specific antigen in the diagnosis of prostate cancer. Br J Urol. 1997;79:920–3.PubMedGoogle Scholar
  18. 18.
    Muti P, Quattrin T, Grant BJ, Krogh V, Micheli A, Schünemann HJ, Ram M, Freudenheim JL, Sieri S, Trevisan M, Berrino F. Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev. 2002;11(11):1361–8.PubMedGoogle Scholar
  19. 19.
    Kaulsay KK. Serum IGF-binding protein-6 and prostate specific antigen in breast cancer. Eur J Endocrinol. 1999;140:164–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, Strax P, Pasternack BS. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst. 1995;87(3):190–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Hasija K, Bagga HK. Alterations of serum cholesterol and serum lipoprotein in breast cancer of women. Indian J Clin Biochem. 2005;20(1):61–6.CrossRefGoogle Scholar
  22. 22.
    Jain D, Ray A, Bahadur AK, Chaturbedi KU, Sood R, Sharma S, Naik SLO, Sharma BK. Status of epidermal growth factor receptors family in hormone dependant carcinomas of the breast and prostate with reference to serum lipids and lipoproteins. Indian J Clin Biochem. 2001;16(1):42–51.CrossRefGoogle Scholar
  23. 23.
    Hulka BS, Stark AT. Breast cancer: cause and prevention. Lancet. 1995;346:883–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Gupta SK. Serum testosterone and dehydroepiandrosterone in Indian breast cancer patients in relation to menstrual status and parity; UICC World Cancer Congress: Bridging the gap: Transforming knowledge into Action, Washington DC, USA, July 8–12, 2006.Google Scholar
  25. 25.
    Bhatavdekar JM, Patel DD, Shah NG, Giri DD, Vora HH, Karelia NH, Trivedi SN, Ghosh N, Suthar TP. Endocrine status in stage II vs. advanced premenopausal and postmenopausal breast cancer patients. Neoplasma. 1992;39(1):39–42.PubMedGoogle Scholar
  26. 26.
    Secreto G, Toniolo P, Pisani P, Recchione C, Cavalleri A, Fariselli G, Totis A, Di Pietro S, Berrino F. Androgens and breast cancer in premenopausal women. Cancer Res. 1989;49:471–6.PubMedGoogle Scholar
  27. 27.
    Magklara A, Grass L, Diamandis EP. Differential steroid hormone regulation of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) in breast cancer cell lines. Breast Cancer Res Treat. 2000;59:263–70.PubMedCrossRefGoogle Scholar
  28. 28.
    Narita D, Raica M, Suciu C, Cîmpean A, Anghel A. Immunohistochemical expression of androgen receptor and prostate-specific antigen in breast cancer. Folia Histochem Cytobiol. 2006;44(3):165–72.PubMedGoogle Scholar
  29. 29.
    Killian CS, Corral DA, Kawinski E, Constantine RI. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-β and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun. 1993;192:940–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Webber MM, Waghray A, Bello D. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res. 1995;1:1089–94.PubMedGoogle Scholar
  31. 31.
    Cohen P, Peehl DM, Graves HCB, Rosenfeld RG. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol. 1994;142:407–15.PubMedCrossRefGoogle Scholar
  32. 32.
    Oh Y, Gucev Z, Ng L, Muller HL, Rosenfeld RG. Antiproliferative actions of insulin-like growth factor binding protein (IGFBP)-3 on human breast cancer cells. Prog Growth Factor Res. 1995;6:503–12.PubMedCrossRefGoogle Scholar
  33. 33.
    Fortier AH, Nelson BJ, Grella DK, Holaday JW. Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst. 1999;91(19):1635–40.PubMedCrossRefGoogle Scholar

Copyright information

© Association of Clinical Biochemists of India 2011

Authors and Affiliations

  • Prakruti Dash
    • 1
    • 2
  • Sanghamitra Pati
    • 1
  • Manaswini Mangaraj
    • 1
  • Pratima Kumari Sahu
    • 1
  • Prakash Chandra Mohapatra
    • 1
  1. 1.Department of BiochemistryS.C.B.Medical CollegeCuttackIndia
  2. 2.Department of BiochemistryIMS and SUM Hospital, Siksha O Anusandhan UniversityBhubaneswarIndia

Personalised recommendations